Mercado de células madre pluripotentes inducidas (iPSC) de América del Norte: tendencias de la industria y pronóstico hasta 2029

Análisis y perspectivas del mercado: mercado de células madre pluripotentes inducidas (iPSC) en América del Norte

Se espera que el mercado de células madre pluripotentes inducidas (iPSC) de América del Norte gane crecimiento de mercado en el período de pronóstico de 2022 a 2029. Data Bridge Market Research analiza que el mercado está creciendo con una CAGR del 9,8% en el período de pronóstico de 2022 a 2029 y se espera que alcance los USD 1.014,30 millones para 2029. El aumento de las actividades de investigación sobre terapias con células madre actúa como impulsor del crecimiento del mercado de células madre pluripotentes inducidas (iPSC).

Las células madre pluripotentes inducidas son un tipo de células derivadas de los tejidos somáticos adultos y reprogramadas con un conjunto de genes y factores para obtener la naturaleza pluripotente. Se añaden ciertos genes y factores para lograr propiedades definidas de las células madre embrionarias. Las células pluripotentes inducidas son casi idénticas a las células donantes y ayudan en el modelado de enfermedades. Los retrovirus se utilizan comúnmente como vectores para reprogramar las células madre pluripotentes inducidas. Las principales aplicaciones de las células madre pluripotentes inducidas son el modelado de enfermedades, el descubrimiento y desarrollo de fármacos, los estudios de toxicidad y las terapias génicas. Se utilizan ampliamente en tratamientos para enfermedades cardiovasculares, diabetes mellitus y varios tipos de cáncer. Las células madre pluripotentes inducidas humanas muestran las propiedades relevantes de la enfermedad, ya que llevan el genotipo específico de la enfermedad, lo que permite nuevas opciones terapéuticas de forma específica para el paciente.

La creciente adopción de terapias con células madre, el creciente sector de la biotecnología con una mayor inversión y la creciente prevalencia de enfermedades crónicas actúan como impulsores del mercado de células madre pluripotentes inducidas (iPSC). Otros factores que se prevé que impulsen el crecimiento del mercado de células madre pluripotentes inducidas (iPSC) en América del Norte incluyen la amplia gama de aplicaciones clínicas de las células madre pluripotentes inducidas y los avances tecnológicos emergentes de las iPSC.

However, the factors such as the high cost associated with stem cell therapies, availability of alternatives for tumor treatment are hampering the growth of the North America induced pluripotent stem cells (iPSCs) market. On the other hand, the rising number of pipeline products, increased interest of personalized medicine and surge in healthcare expenditure act as an opportunity for the growth of the North America induced pluripotent stem cells (iPSCs) market. The stringent rules and regulations and Genomic instability of IPSC is the key market challenge faced in the North America induced pluripotent stem cells (iPSCs) market.

The induced pluripotent stem cells (iPSCs) market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the induced pluripotent stem cells (iPSCs) market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Induced Pluripotent Stem Cells (iPSCs) Market Scope and Market Size

The induced pluripotent stem cells (iPSCs) market is segmented on basis of cell source, type, product, applications, end users and distribution channel The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

North America induced pluripotent stem cells (iPSCs) market is categorized into six notable segments based on the cell source, type, product, applications, end users and distribution channel.

• On the basis of cell source, the North America induced pluripotent stem cells (iPSCs) market is segmented into skin cells and blood cells. In 2022, skin cells segment is expected to dominate the market due to wide availability of fibroblast and keratinocyte cells from skin surface for stem cell differentiation.
• On the basis of type, the North America induced pluripotent stem cells (iPSCs) market is segmented into human IPSCs and mouse IPSCs. In 2022, human IPSCs segment is expected to dominate the market as the source of cells from patients with certain diseases can be specifically used for studying the stage of disorder.
• On the basis of product, the North America induced pluripotent stem cells (iPSCs) market is segmented into instruments, consumables & kits and services. In 2022, consumables & kits segment is expected to dominate the market due to wide application of the stem cell kits in disease modelling and drug toxicity testing.
• On the basis of application, the North America induced pluripotent stem cells (iPSCs) market is segmented into academic research, regenerative medicine, cellular therapy, toxicology screening, drug discovery and development, disease modelling, stem cell banking, 3D bioprinting and others. In 2022, drug discovery and development segment is expected to dominate the market as stem cells are used in innovative novel therapeutic invention for chronic diseases.
• On the basis of end-users, the North America induced pluripotent stem cells (iPSCs) market is segmented into biotechnology & pharmaceutical companies, research laboratories, diagnostic laboratories and others. In 2022, biotechnology & pharmaceutical companies segment is expected to dominate the market due to high number of strategic initiatives taken by key players in the region.
• On the basis of distribution channel, the North America induced pluripotent stem cells (iPSCs) market is segmented into direct tender and retail sales. In 2022, direct tender segment is expected to dominate the market due to high number of suppliers and transporting facilities managed by key manufacturers directly.

Induced Pluripotent Stem Cells (iPSCs) Market Country Level Analysis

The induced pluripotent stem cells (iPSCs) market is analyzed and market size information is provided by the country, cell source, type, product, applications, end users and distribution channel as referenced above.

The countries covered in the induced pluripotent stem cells (iPSCs) market report are the U.S., Canada and Mexico.

Biotechnology & Pharmaceutical companies segment.in U.S of North American region is expected to grow with the highest growth rate in the forecast period of 2022 to 2029 because of increasing usage of stem cell technology. The Biotechnology & Pharmaceutical companies segment in Canada is second dominating the market owing to increasing cases of chronic diseases and high adoption of stem cell sources for better therapies. Mexico is third in leading the growth of the market and Biotechnology & Pharmaceutical companies segment is dominating in this country due to increasing number of biotechnology centers and research activities.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of North America brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Growing Strategic Activities by Major Market Players to Enhance the Awareness for Induced Pluripotent Stem Cells (iPSCs) Treatment, is Boosting the Market Growth of Induced Pluripotent Stem Cells (iPSCs) Market.

The induced pluripotent stem cells (iPSCs) market also provides you with detailed market analysis for every country growth in particular market. Additionally, it provides the detail information regarding the market players’ strategy and their geographical presence. The data is available for historic period 2011 to 2020.

Competitive Landscape and Induced Pluripotent Stem Cells (iPSCs) Market Share Analysis

Induced pluripotent stem cells (iPSCs) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to induced pluripotent stem cells (iPSCs) market.

The major companies which are dealing in the induced pluripotent stem cells (iPSCs) are Thermo Fisher Scientific Inc., FUJIFILM Corporation, LumaCyte,  Horizon Discovery Ltd., Hopstem Biotechnology LLC., Takara Bio Inc., Cell Applications, Inc., Citius Pharmaceuticals, Inc., Lonza., Evotec SE., Fate Therapeutics, Universal Cells Inc. (An Astellas Company), Axol Bioscience Ltd., R & D Systems, Inc., Charles River Laboratories International, Inc., Corning Incorporated, REPROCELL Inc., Applied StemCell., Merck KGaA, GeneCopoeia, Inc. and among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Many contract and agreement are also initiated by the companies’ worldwide which are also accelerating the induced pluripotent stem cells (iPSCs) market.

For instance,

• In February 2021, Thermo Fisher Scientific Inc. announced it has won six awards in the annual CMO Leadership Awards. The awards, presented by Life Science Leader and Outsourced Pharma, recognize top contract manufacturing partners as evaluated by biopharma and biotech companies. It is estimated that this recognition anticipated to strengthen company’s footprints in North America market and leading to upsurge company’s growth in the coming years.
• In June 2020, the LumaCyte collaborated with Catalent who are the North America provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. This collaboration aided in expanding the company’s stem cell technology product Radiance and its application.

La colaboración, el lanzamiento de productos, la expansión comercial, los premios y reconocimientos, las empresas conjuntas y otras estrategias de los actores del mercado están mejorando la presencia de la empresa en el mercado de bombas de infusión veterinaria, lo que también brinda beneficios para el crecimiento de las ganancias de la organización.

SKU-66912